FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012812077> ?p ?o ?g. }

• W2012812077 endingPage "406" @default.
• W2012812077 startingPage "402" @default.
• W2012812077 abstract "In advanced non-small-cell lung cancer (NSCLC), substantial similarities in terms of treatment efficacy and survival have emerged over the years between the different systemic chemotherapy regimens used. More recently, other topics such as histotype, maintenance therapy and quality of life have been explored to ameliorate this plateau. We present the treatment rationale and study design of the ERACLE (induction pEmetrexed and cisplatin followed by maintenance pemetRexed versus cArboplatin-paCLitaxel and bEvacizumab followed by maintenance bevacizumab) trial. Patients enrolled in the ERACLE trial are randomized between combination treatment arms: (A) cisplatin 75 mg/m(2) day 1 and pemetrexed 500 mg/m(2) day 1, every 3 weeks for six cycles followed (in responders or with stable disease) by pemetrexed 500 mg/m(2) day 1, every 3 weeks until progression; and (B) carboplatin AUC 6 day 1, plus paclitaxel 200 mg/m(2) day 1 and plus bevacizumab 15 mg/kg, every 3 weeks for six cycles followed (in responders or patients with stable disease) by bevacizumab 15 mg/kg every 3 weeks until progression. The primary objective of the study is to evaluate the difference in terms of quality of life between treatment arms. together with co-primary endpoints represented by the EuroQoL group (EQ-5D) questionnaire total score and the EQ-5D visual analog scale. Secondary endpoints are the evaluation of treatment activity and exploratory evaluation of treatment efficacy." @default.
• W2012812077 created "2016-06-24" @default.
• W2012812077 creator A5013748999 @default.
• W2012812077 creator A5017359826 @default.
• W2012812077 creator A5021158045 @default.
• W2012812077 creator A5021934862 @default.
• W2012812077 creator A5022124014 @default.
• W2012812077 creator A5024342569 @default.
• W2012812077 creator A5036207986 @default.
• W2012812077 creator A5045086403 @default.
• W2012812077 creator A5046559582 @default.
• W2012812077 creator A5062643447 @default.
• W2012812077 creator A5067997872 @default.
• W2012812077 creator A5080212287 @default.
• W2012812077 creator A5083911666 @default.
• W2012812077 creator A5089905867 @default.
• W2012812077 date "2011-11-01" @default.
• W2012812077 modified "2023-09-27" @default.
• W2012812077 title "Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)" @default.
• W2012812077 cites W1814699096 @default.
• W2012812077 cites W2012368323 @default.
• W2012812077 cites W2037139573 @default.
• W2012812077 cites W2045381419 @default.
• W2012812077 cites W2068990207 @default.
• W2012812077 cites W2069422280 @default.
• W2012812077 cites W2088720324 @default.
• W2012812077 cites W2098428600 @default.
• W2012812077 cites W2099725888 @default.
• W2012812077 cites W2100667077 @default.
• W2012812077 cites W2101713088 @default.
• W2012812077 cites W2109541641 @default.
• W2012812077 cites W2110835998 @default.
• W2012812077 cites W2112621029 @default.
• W2012812077 cites W2127101185 @default.
• W2012812077 cites W2128611498 @default.
• W2012812077 cites W2138297714 @default.
• W2012812077 cites W2145835533 @default.
• W2012812077 cites W2149564130 @default.
• W2012812077 cites W2152755651 @default.
• W2012812077 cites W2153477391 @default.
• W2012812077 cites W2153836018 @default.
• W2012812077 cites W2162724777 @default.
• W2012812077 cites W2163351155 @default.
• W2012812077 cites W2167571044 @default.
• W2012812077 cites W2414584701 @default.
• W2012812077 cites W2473786944 @default.
• W2012812077 cites W2601846828 @default.
• W2012812077 cites W3145077989 @default.
• W2012812077 doi "https://doi.org/10.1016/j.cllc.2011.06.006" @default.
• W2012812077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21831718" @default.
• W2012812077 hasPublicationYear "2011" @default.
• W2012812077 type Work @default.
• W2012812077 sameAs 2012812077 @default.
• W2012812077 citedByCount "10" @default.
• W2012812077 countsByYear W20128120772012 @default.
• W2012812077 countsByYear W20128120772013 @default.
• W2012812077 countsByYear W20128120772018 @default.
• W2012812077 countsByYear W20128120772022 @default.
• W2012812077 crossrefType "journal-article" @default.
• W2012812077 hasAuthorship W2012812077A5013748999 @default.
• W2012812077 hasAuthorship W2012812077A5017359826 @default.
• W2012812077 hasAuthorship W2012812077A5021158045 @default.
• W2012812077 hasAuthorship W2012812077A5021934862 @default.
• W2012812077 hasAuthorship W2012812077A5022124014 @default.
• W2012812077 hasAuthorship W2012812077A5024342569 @default.
• W2012812077 hasAuthorship W2012812077A5036207986 @default.
• W2012812077 hasAuthorship W2012812077A5045086403 @default.
• W2012812077 hasAuthorship W2012812077A5046559582 @default.
• W2012812077 hasAuthorship W2012812077A5062643447 @default.
• W2012812077 hasAuthorship W2012812077A5067997872 @default.
• W2012812077 hasAuthorship W2012812077A5080212287 @default.
• W2012812077 hasAuthorship W2012812077A5083911666 @default.
• W2012812077 hasAuthorship W2012812077A5089905867 @default.
• W2012812077 hasConcept C126322002 @default.
• W2012812077 hasConcept C141071460 @default.
• W2012812077 hasConcept C143998085 @default.
• W2012812077 hasConcept C168563851 @default.
• W2012812077 hasConcept C203092338 @default.
• W2012812077 hasConcept C2776256026 @default.
• W2012812077 hasConcept C2776694085 @default.
• W2012812077 hasConcept C2777240266 @default.
• W2012812077 hasConcept C2777292972 @default.
• W2012812077 hasConcept C2777802072 @default.
• W2012812077 hasConcept C2778239845 @default.
• W2012812077 hasConcept C2778283404 @default.
• W2012812077 hasConcept C2781451048 @default.
• W2012812077 hasConcept C71924100 @default.
• W2012812077 hasConceptScore W2012812077C126322002 @default.
• W2012812077 hasConceptScore W2012812077C141071460 @default.
• W2012812077 hasConceptScore W2012812077C143998085 @default.
• W2012812077 hasConceptScore W2012812077C168563851 @default.
• W2012812077 hasConceptScore W2012812077C203092338 @default.
• W2012812077 hasConceptScore W2012812077C2776256026 @default.
• W2012812077 hasConceptScore W2012812077C2776694085 @default.
• W2012812077 hasConceptScore W2012812077C2777240266 @default.
• W2012812077 hasConceptScore W2012812077C2777292972 @default.
• W2012812077 hasConceptScore W2012812077C2777802072 @default.
• W2012812077 hasConceptScore W2012812077C2778239845 @default.

• next